Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 11.77
(8.88%)
CNY 11.77
(8.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -332.65 Million CNY | -86.95% |
| 2022 | -208.72 Million CNY | -6.97% |
| 2021 | -175.2 Million CNY | -54.94% |
| 2020 | -123.53 Million CNY | -309.69% |
| 2019 | 52.38 Million CNY | -70.13% |
| 2018 | 110.87 Million CNY | -46.32% |
| 2017 | 327.62 Million CNY | 0.77% |
| 2016 | 318.37 Million CNY | 11.58% |
| 2015 | 244.81 Million CNY | 64.87% |
| 2014 | 181.64 Million CNY | 53.05% |
| 2013 | 115 Million CNY | -39.03% |
| 2012 | 204.92 Million CNY | 44.73% |
| 2011 | 129.94 Million CNY | 76.94% |
| 2010 | 69.68 Million CNY | 52.65% |
| 2009 | 47.62 Million CNY | 92.69% |
| 2008 | 24.84 Million CNY | 354.71% |
| 2007 | 5.53 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 6.22 Million CNY | 92.34% |
| 2024 Q3 | -5.87 Million CNY | -168.13% |
| 2024 Q1 | -3.54 Million CNY | 102.5% |
| 2023 FY | - CNY | -86.95% |
| 2023 Q1 | -46.97 Million CNY | 24.7% |
| 2023 Q2 | -105.18 Million CNY | -123.91% |
| 2023 Q4 | -179.34 Million CNY | -480.58% |
| 2023 Q3 | -30.89 Million CNY | 70.63% |
| 2022 Q4 | -62.38 Million CNY | 13.28% |
| 2022 FY | - CNY | -6.97% |
| 2022 Q1 | -24.41 Million CNY | 71.21% |
| 2022 Q2 | -57.07 Million CNY | -133.8% |
| 2022 Q3 | -71.94 Million CNY | -26.05% |
| 2021 Q2 | -36.81 Million CNY | -97.19% |
| 2021 Q1 | -18.66 Million CNY | 69.2% |
| 2021 FY | - CNY | -54.94% |
| 2021 Q4 | -84.78 Million CNY | -27.47% |
| 2021 Q3 | -66.51 Million CNY | -80.69% |
| 2020 FY | - CNY | -309.69% |
| 2020 Q4 | -60.59 Million CNY | -207.56% |
| 2020 Q3 | -19.7 Million CNY | 50.97% |
| 2020 Q2 | -40.18 Million CNY | -66.79% |
| 2020 Q1 | -24.09 Million CNY | 22.12% |
| 2019 FY | - CNY | -70.13% |
| 2019 Q3 | 7.88 Million CNY | -27.13% |
| 2019 Q4 | -30.93 Million CNY | -492.61% |
| 2019 Q2 | 10.81 Million CNY | -68.39% |
| 2019 Q1 | 34.2 Million CNY | 227.38% |
| 2018 FY | - CNY | -46.32% |
| 2018 Q1 | 50.84 Million CNY | -39.01% |
| 2018 Q4 | 10.44 Million CNY | -55.1% |
| 2018 Q3 | 23.26 Million CNY | -34.5% |
| 2018 Q2 | 35.52 Million CNY | -30.13% |
| 2017 Q4 | 83.36 Million CNY | 0.49% |
| 2017 Q1 | 65.41 Million CNY | -26.78% |
| 2017 Q2 | 69.79 Million CNY | 6.69% |
| 2017 Q3 | 82.95 Million CNY | 18.86% |
| 2017 FY | - CNY | 0.77% |
| 2016 FY | - CNY | 11.58% |
| 2016 Q1 | 63.12 Million CNY | -32.34% |
| 2016 Q4 | 89.34 Million CNY | 6.55% |
| 2016 Q2 | 65.35 Million CNY | 3.55% |
| 2016 Q3 | 83.84 Million CNY | 28.29% |
| 2015 Q3 | 66.46 Million CNY | 17.67% |
| 2015 FY | - CNY | 64.87% |
| 2015 Q4 | 93.28 Million CNY | 40.35% |
| 2015 Q2 | 56.48 Million CNY | 3.21% |
| 2015 Q1 | 54.72 Million CNY | 8.08% |
| 2014 Q4 | 50.63 Million CNY | -21.1% |
| 2014 FY | - CNY | 53.05% |
| 2014 Q1 | 22.48 Million CNY | 263.22% |
| 2014 Q2 | 20.1 Million CNY | -10.62% |
| 2014 Q3 | 64.17 Million CNY | 219.29% |
| 2013 Q3 | 8.64 Million CNY | -84.44% |
| 2013 Q4 | -13.77 Million CNY | -259.43% |
| 2013 FY | - CNY | -39.03% |
| 2013 Q1 | 52.76 Million CNY | 3.24% |
| 2013 Q2 | 55.55 Million CNY | 5.28% |
| 2012 Q1 | 35.7 Million CNY | -45.59% |
| 2012 Q4 | 51.11 Million CNY | 44.33% |
| 2012 Q2 | 58.21 Million CNY | 63.04% |
| 2012 Q3 | 35.41 Million CNY | -39.17% |
| 2012 FY | - CNY | 44.73% |
| 2011 Q1 | 14.08 Million CNY | -42.64% |
| 2011 FY | - CNY | 76.94% |
| 2011 Q3 | 23.07 Million CNY | 8.16% |
| 2011 Q4 | 65.62 Million CNY | 184.45% |
| 2011 Q2 | 21.33 Million CNY | 51.48% |
| 2010 Q2 | 14.8 Million CNY | -1.45% |
| 2010 FY | - CNY | 52.65% |
| 2010 Q3 | 13.61 Million CNY | -8.05% |
| 2010 Q1 | 15.02 Million CNY | 0.0% |
| 2010 Q4 | 24.55 Million CNY | 80.33% |
| 2009 FY | - CNY | 92.69% |
| 2008 FY | - CNY | 354.71% |
| 2007 FY | - CNY | 0.0% |